Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

97.62 +0.19 (+0.19%)
Streaming Delayed Price Updated: 10:26 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,968,405
Open 97.72
Bid (Size) 97.59 (5)
Ask (Size) 97.62 (1)
Prev. Close 97.44
Today's Range 96.95 - 98.43
52wk Range 94.48 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool

Performance

YTD
-13.79%
-13.79%
1 Month
-8.20%
-8.20%
3 Month
-15.86%
-15.86%
6 Month
-25.53%
-25.53%
1 Year
-4.49%
-4.49%

More News

Read More
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Via Benzinga
Merck Announces First-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
From Merck & Co., Inc.
Via Business Wire
Not-So-Big Pharma
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Via Benzinga
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Via Investor's Business Daily
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Merck to Participate in the Jefferies London Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
From Merck & Co., Inc.
Via Business Wire
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
From Merck & Co., Inc.
Via Business Wire
Biotech Stocks Are Rallying: What Is Your Playbook?
Via Talk Markets
3 Stocks Poised for a Breakout
Via The Motley Fool
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.